Shots:
- The SURPASS-4 study evaluates the efficacy & safety of tirzepatide (5/10/15mg) vs insulin glargine in 2002 adults in a ratio (1:1:1:3) with T2D inadequately controlled with 1 & up to 3 oral antihyperglycemic medications who have increased CV risk
- The study met its 1EPs & 2EPs i.e., superior A1C & body weight reductions for both estimands @52wks. A1C reduction (-2.24% / -2.43%/ -2.58% vs -1.44%); weight reduction (-7.1/ -9.5/ -11.7kg vs +1.9 kg); patients achieving A1C <7% (81%/ 88%/ 91% vs 51%); patients achieving A1C <5.7% (23%/ 33%/ 43% vs 3%) respectively
- Additionally, the overall safety profile was consistent with safety results @52wks. & no new findings were observed @~104 weeks.
Click here to read the full press release/ article | Ref: PR Newswire | Image: The Indian Express
The post Lilly Published Results of Tirzepatide in SURPASS-4 Study for the Treatment of Type 2 Diabetes in The Lancet first appeared on PharmaShots.
